Everstone Acquires Majority Stake in Rubicon Research
by Suman Gupta
Mumbai, October 24, 2016 : The Everstone
Group has bought a 70% stake in Mumbai-based Rubicon Research Pvt. Ltd., a
pioneering drug delivery technology company in India, for a total outlay of Rs
220 crore (US$ 33 million). Along with a US$ 20 million investment directly
into the business, the deal includes acquiring stakes from Kotak Private Equity
and a private investor. Rubicon is a world-class outsourcing partner to the
global pharmaceutical industry and its proprietary technologies provide
solutions for bioavailability enhancement, gastric retention, taste masking,
and customising the release profiles of drugs. Rubicon also offers lifecycle
management services for pharmaceutical products. Rubicon also has a US
FDA-approved manufacturing plant at Ambernath in Maharashtra, with a capacity
of 800 million tablets and it has refocused its business on creating its own
Abbreviated New Drug Applications (ANDAs)/New Drug Applications (NDAs) for the
global market. “Rubicon has an excellent record of providing cutting-edge
solutions to the healthcare and pharmaceutical industry,” said Sameer Sain,
Co-Founder and Managing Partner of the Everstone Group. “We are excited about
enhancing its capabilities,” Sameer added. Rubicon Founder and CEO Dr. Pratibha
Pilgaonkar said: “We welcome this partnership with Everstone and believe, with
their deep managerial and operational expertise, capital infusion, and global
connectivity, we will be able to significantly accelerate our growth.” This
investment will be fourth investment from Everstone’s latest PE fund (Everstone
Capital Partners III) and was led by Deep Mishra, an Everstone MD who focuses
on consumer and pharmaceutical investments for the Group. Deep will be joining
the board of directors of Rubicon.
About Everstone Group The Everstone Group is
a premier India and Southeast Asia focused private equity and real estate
investment firm with assets under management of USD $3.3 billion. Headquartered
in Singapore, Everstone has around 200 people working across five
offices—Singapore, Mumbai, Delhi, Bengaluru, and Mauritius. Everstone has been
awarded ‘Private Equity Firm of the Year in India’ by Private Equity
International for five consecutive years.
About Rubicon Rubicon Research is a
pioneer Drug Delivery Technology company in India and is recognized as a world
class outsourcing partner in pharmaceutical industry. Rubicon’s proprietary
technologies provide solutions for bioavailability enhancement, gastric retention,
taste masking, and customising the release profiles. Rubicon has a US
FDA-approved manufacturing plant and is bringing complex generics into the
regulated markets of US and Europe. For more information, visit
http://www.rubicon.co.in/
Comments
Post a Comment